Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is ...

Mirikizumab (Omvoh) is effective in inducing a clinical response in adults with moderate-to-severe ulcerative colitis and ...

Ulcerative colitis (UC) is one of the most common inflammatory bowel diseases, a lifelong condition that can cause chronic ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...

Week held in Berlin, Germany, an informative session explored emerging approaches for the management of ulcerative colitis (UC), ranging from surgical interventions to updated treatment guidelines and ...

A toxin-secreting gut bacterium may fuel ulcerative colitis by killing protective immune cells that maintain intestinal homeostasis, according to a new study. The findings suggest potential for new ...

A gut microbe secretes macrophage-targeting factors, rendering the intestinal layer vulnerable to ulcerative colitis, ...